NCT06631404 Renal Arterial Resistive Index as a Noninvasive Biomarker of Disease Activity in Lupus Nephritis Patients
| NCT ID | NCT06631404 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sohag University |
| Condition | Lupus Nephritis |
| Study Type | OBSERVATIONAL |
| Enrollment | 55 participants |
| Start Date | 2024-10-01 |
| Primary Completion | 2025-10-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 55 participants in total. It began in 2024-10-01 with a primary completion date of 2025-10-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Systemic Lupus Erthymatosous (SLE) is achronic inflammatory multi system auto immue disease characterized by pathogenic auto anti bodies production against nuclear structures (Bolouri et al.,2022), SLE affecting mainly woemn of childbearing age and is chracterized by unpredictable flares and remissions , disease variety varied from mild episode disorder to arpidly progressive life -threatening illness.. LN is diagnosed by either the presence of proteinuria \>0.5g/day. active urinary sediment , or an unexplained rise in serum creatinine there fore , identifying new invasive biomarkers of LN severity and outcome is mandatory, Renal Arterial resistive index ( RRI) is anon invasive biomarker that has been studied as apotential indicator of disease activity in LN patients.
Eligibility Criteria
Inclusion Criteria: * Aged ≥18 years. * SLE patients fulfilling the SLE International Collaborating Clinics (SLICC) classification criteria and matched controls. * Patients cooperative and can answer questions. * Patients who are able and willing to give written informed consent. Exclusion Criteria: * • Individuals with other autoimmune diseases. * Diabetes. * Hypertension. * Heart failure. * Hepatic diseases. * Chronic renal failure. * Renal artery stenosis. * Renal vein thrombosis. * Intrarenal arteriovenous fistula. * Obstructive nephropathy. * Urinary tract obstruction that could affect RI of intra renal arteries. * Un cooperative patients. * Patients not able and willing to give written informed consent.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06631404 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Lupus Nephritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06631404 currently recruiting?
Yes, NCT06631404 is actively recruiting participants. Contact the research team at doaa_rabea_post@med.sohag.edu.eg for enrollment information.
Where is the NCT06631404 trial being conducted?
This trial is being conducted at Sohag, Egypt.
Who is sponsoring the NCT06631404 clinical trial?
NCT06631404 is sponsored by Sohag University. The trial plans to enroll 55 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.